Terms: = Head and neck cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809
1237 results:
1. Identification of PANoptosis-related biomarkers and analysis of prognostic values in head and neck squamous cell carcinoma.
Yang P; Huang G; Li Y; Yu L; Yin Z; Li Q
Sci Rep; 2024 Apr; 14(1):9824. PubMed ID: 38684755
[TBL] [Abstract] [Full Text] [Related]
2. Annexin A2 combined with TTK accelerates esophageal cancer progression via the Akt/mtor signaling pathway.
Liu R; Lu Y; Li J; Yao W; Wu J; Chen X; Huang L; Nan D; Zhang Y; Chen W; Wang Y; Jia Y; Tang J; Liang X; Zhang H
Cell Death Dis; 2024 Apr; 15(4):291. PubMed ID: 38658569
[TBL] [Abstract] [Full Text] [Related]
3. Lactoferrin mediates epithelial-mesenchymal transformation by regulating the PI3K/AKT/mtor pathway to inhibit nasopharyngeal carcinoma metastasis.
Xu M; Fan Y; Zou G; Yang Q; Xu F
Cell Mol Biol (Noisy-le-grand); 2024 Mar; 70(3):130-135. PubMed ID: 38650146
[TBL] [Abstract] [Full Text] [Related]
4. Augmented ERO1α upon mtorC1 activation induces ferroptosis resistance and tumor progression via upregulation of SLC7A11.
Wang Z; Zong H; Liu W; Lin W; Sun A; Ding Z; Chen X; Wan X; Liu Y; Hu Z; Zhang H; Li H; Liu Y; Li D; Zhang S; Zha X
J Exp Clin Cancer Res; 2024 Apr; 43(1):112. PubMed ID: 38610018
[TBL] [Abstract] [Full Text] [Related]
5. HSP90B1 regulates autophagy
Li C; Lin X; Su J
PeerJ; 2024; 12():e17028. PubMed ID: 38590708
[TBL] [Abstract] [Full Text] [Related]
6. PQR309, a dual PI3K/mtor inhibitor, synergizes with gemcitabine by impairing the GSK-3β and STAT3/HSP60 signaling pathways to treat nasopharyngeal carcinoma.
Cao J; Zeng K; Chen Q; Yang T; Lu F; Lin C; Zhan J; Ma W; Zhou T; Huang Y; Luo F; Zhao H
Cell Death Dis; 2024 Mar; 15(3):237. PubMed ID: 38555280
[TBL] [Abstract] [Full Text] [Related]
7. c-MET pathway in human malignancies and its targeting by natural compounds for cancer therapy.
Mohan CD; Shanmugam MK; Gowda SGS; Chinnathambi A; Rangappa KS; Sethi G
Phytomedicine; 2024 Jun; 128():155379. PubMed ID: 38503157
[TBL] [Abstract] [Full Text] [Related]
8. Metformin in Esophageal Carcinoma: Exploring Molecular Mechanisms and Therapeutic Insights.
Papadakos SP; Argyrou A; Lekakis V; Arvanitakis K; Kalisperati P; Stergiou IE; Konstantinidis I; Schizas D; Koufakis T; Germanidis G; Theocharis S
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474224
[TBL] [Abstract] [Full Text] [Related]
9. PHA-665752's Antigrowth and Proapoptotic Effects on HSC-3 Human Oral cancer Cells.
Yadav AK; Wang S; Shin YM; Jang BC
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474118
[TBL] [Abstract] [Full Text] [Related]
10. Differential modulation of PI3K/Akt/mtor activity by EGFR inhibitors: A rationale for co-targeting EGFR and PI3K in cisplatin-resistant HNSCC.
Liao J; Yang Z; Azarbarzin S; Cullen KJ; Dan H
Head Neck; 2024 May; 46(5):1126-1135. PubMed ID: 38429897
[TBL] [Abstract] [Full Text] [Related]
11. Evaluation of Five-year Overall Survival Rates Among 18,331 head and neck cancer Patients Exposed to Different Targeted Therapies Through Real-world Data in a Case-controlled Study.
Baudrexl J; Sakkas A; Pietzka S; Derka S; Vairaktari G; Scheurer M; Schramm A; Wilde F; Ebeling M
Anticancer Res; 2024 Mar; 44(3):1247-1270. PubMed ID: 38423635
[TBL] [Abstract] [Full Text] [Related]
12. Different Impacts of DNA-PK and mtor Kinase Inhibitors in Combination with Ionizing Radiation on HNSCC and Normal Tissue Cells.
Klieber N; Hildebrand LS; Faulhaber E; Symank J; Häck N; Härtl A; Fietkau R; Distel LV
Cells; 2024 Feb; 13(4):. PubMed ID: 38391917
[TBL] [Abstract] [Full Text] [Related]
13. Enhancing CAR-T cell metabolism to overcome hypoxic conditions in the brain tumor microenvironment.
Hatae R; Kyewalabye K; Yamamichi A; Chen T; Phyu S; Chuntova P; Nejo T; Levine LS; Spitzer MH; Okada H
JCI Insight; 2024 Apr; 9(7):. PubMed ID: 38386420
[TBL] [Abstract] [Full Text] [Related]
14. Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma.
Nghiemphu PL; Vitte J; Dombi E; Nguyen T; Wagle N; Ishiyama A; Sepahdari AR; Cachia D; Widemann BC; Brackmann DE; Doherty JK; Kalamarides M; Giovannini M
J Neurooncol; 2024 Apr; 167(2):339-348. PubMed ID: 38372904
[TBL] [Abstract] [Full Text] [Related]
15. Exosomal circMACF1 drives PI3K/AKT/mtor-mediated autophagy suppression in laryngeal squamous cell carcinoma.
Zhu Y; Duan C; Gui Y; Chen D; Su X
Cell Mol Biol (Noisy-le-grand); 2024 Jan; 70(1):179-185. PubMed ID: 38372097
[TBL] [Abstract] [Full Text] [Related]
16. Artesunate-loaded solid lipid nanoparticles resist esophageal squamous cell carcinoma by inducing Ferroptosis through inhibiting the AKT/mtor signaling.
Xia Y; Tang Y; Huang Z; Ke N; Zheng Y; Zhuang W; Zhang Y; Yin X; Tu M; Chen J; Wang Y; Huang Y
Cell Signal; 2024 May; 117():111108. PubMed ID: 38369266
[TBL] [Abstract] [Full Text] [Related]
17. PPARα Agonism Enhances Immune Response to Radiotherapy While Dietary Oleic Acid Results in Counteraction.
Ross RB; Gadwa J; Yu J; Darragh LB; Knitz MW; Nguyen D; Olimpo NA; Abdelazeem KNM; Nguyen A; Corbo S; Van Court B; Beynor J; Neupert B; Saviola AJ; D'Alessandro A; Karam SD
Clin Cancer Res; 2024 May; 30(9):1916-1933. PubMed ID: 38363297
[TBL] [Abstract] [Full Text] [Related]
18. Deep response to a combination of mtor inhibitor temsirolimus and dual immunotherapy of nivolumab/ipilimumab in poorly differentiated thyroid carcinoma with
Oh Y; Park JH; Djunadi TA; Shah Z; Chung LI; Chae YK
Front Endocrinol (Lausanne); 2024; 15():1304188. PubMed ID: 38356955
[TBL] [Abstract] [Full Text] [Related]
19. Inhibition of PTPN3 Expressed in Activated Lymphocytes Enhances the Antitumor Effects of Anti-PD-1 Therapy in head and neck cancer, Especially in Hypoxic Environments.
Masuda S; Onishi H; Iwamoto N; Imaizumi A; Koga S; Nagao S; Sakanashi K; Itoyama S; Fujimura A; Komune N; Kogo R; Umebayashi M; Morisaki T; Nakagawa T
J Immunother; 2024 Apr; 47(3):89-97. PubMed ID: 38297883
[TBL] [Abstract] [Full Text] [Related]
20. GLP-1 receptor agonist liraglutide inhibits the proliferation and migration of thyroid cancer cells.
Zhang X; Zhang L; Wang B; Zhang X; Gu L; Guo K; Zhang X; Zhou Z
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):221-225. PubMed ID: 38279433
[TBL] [Abstract] [Full Text] [Related]
[Next]
